Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trial
Official title:
RPSA as a Potential Prognostic Biomarker of PDAC
PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity. Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.
The aim of this study is to explore the potential implication of RPSA as prognostic biomarker of PDAC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04622423 -
Advanced Therapies for Liver Metastases
|
||
| Recruiting |
NCT05379985 -
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
|
Phase 1 | |
| Recruiting |
NCT05706129 -
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02782182 -
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
|
Phase 1 | |
| Recruiting |
NCT03977233 -
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT03549000 -
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
|
Phase 1 | |
| Completed |
NCT06147154 -
Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients
|
||
| Recruiting |
NCT05605522 -
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
|
Phase 1 | |
| Not yet recruiting |
NCT06261359 -
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03032913 -
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
|
||
| Active, not recruiting |
NCT04883450 -
PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer
|
||
| Completed |
NCT03811652 -
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06044064 -
"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
|
||
| Recruiting |
NCT04990609 -
A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer
|
Phase 2 |